Incyte | INCY - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agenus USD 38.52M 3.2M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Amgen USD 541M 1000K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Exelixis USD 244.68M 4.21M 2026-09
Gilead Sciences USD 1.24B 1000K 2026-06
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.65M 86K 2026-06
Merck USD 2.47B 1.05M 2026-06
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novartis USD 1.89B 12.09M 2026-09
Novartis USD 1.89B 19.47M 2026-09
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 83.33M 445K 2026-06
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.5M 200K 2026-09